Strive Health Raises $140 Million Led by Alphabet’s CapitalG to Tackle $410 Billion of Unmanaged Kidney Disease Spend

Strive Health, the national leader in value-based kidney care, today announced that the company secured a $140 million Series B round of funding led by CapitalG, Alphabet’s independent growth fund. Redpoint also joins current investors NEA, Town Hall Ventures, Ascension Ventures and Echo Ventures to complete the round. The financing will support the growing demand for Strive’s innovative whole-patient solution for kidney disease populations. This brings Strive’s total funding to $223.5 million.

Strive’s model combines advanced technology with high-touch patient care to slow kidney disease progression, prevent unnecessary and costly hospitalizations, and expand access to optimal renal replacement therapies such as home dialysis and transplants. The growing national spotlight on kidney care and the demand for value-based healthcare solutions has helped Strive more than double its presence in regional markets and grow its employee base by more than 600% in the last year.

The new partnership with CapitalG is expected to amplify Strive’s position as the leader in value-based kidney care through growth capital and unique access to Google’s and Alphabet’s expertise to support product and go-to-market innovation.

“Chronic and end-stage kidney disease patients continue to be underserved by the current healthcare system. Strive has built an industry-leading kidney care solution that has the potential to transform patients’ lives,” said Sumi Das, partner at CapitalG. “After extensively studying the landscape, we determined that Strive’s technology, care delivery model, and team were best-in-class in the rapidly emerging kidney care segment. We are excited to partner with the Strive team to improve patient outcomes and significantly drive down healthcare costs.”

Read Full Story